Insights On Upstream Manufacturing

81. Extrahepatic Delivery Of mRNA-LNP To Spleen 6/19/2026

    In vivo CAR-T approaches aim to reprogram T cells directly in the body using targeted lipid nanoparticles. Improved delivery to immune organs highlights new potential for scalable cell therapies.

82. Discover A System That Can Be Used With Various Cell Culture Media 6/19/2026

    Evolving CAR T cell therapies are raising the bar for manufacturing. Advances in cell expansion and the shift to serum-free media are redefining how scalable, future-ready processes are designed.

83. Developing CAR T Therapies With A Cell Therapy Manufacturing Platform 6/19/2026

    Advances in CAR T cell engineering are expanding clinical potential, but manufacturing complexity limits scale. Integrated, automated workflows offer a path to consistent and efficient production.

84. A Practical Guide To Autologous CAR T Manufacturing 6/19/2026

    Early process decisions shape scalability, consistency, and compliance in autologous CAR T manufacturing. Learn where variability emerges across the workflow and how to plan ahead.

85. The Invaluable Asset Driving Advanced Therapies Forward 6/19/2026

    Cell therapies are advancing rapidly, but manufacturing delays still limit patient access. Improving operational understanding, reducing risk, and strengthening collaboration may be just as critical.

86. Achieving High CAR T Cell Transduction Using An Automated Platform 6/19/2026

    Automation is reshaping CAR T manufacturing. A modular, closed approach with digital integration supports efficient workflows while maintaining critical functional performance under GMP conditions.

87. Accelerating Autologous CAR T Cell Expansion With Automation 6/19/2026

    Scaling CAR T manufacturing demands high expansion without exhaustion. Examine integrated, semi-automated approaches with digital traceability that can improve consistency and preserve cell function.

88. Evaluating CAR T Cell Therapy Processing 6/19/2026

    Serum-free media is reshaping CAR T manufacturing. Gain insight into how media-agnostic platforms offer the flexibility to adapt workflows without re-optimization, helping teams streamline processes.

89. Generate Stable High-Producing Clones In 14 Weeks 6/18/2026

    Rising complexity is putting pressure on cell line development. Discover a streamlined approach that enables rapid generation of stable clones with strong titers and long-term consistency.

90. Where Speed Meets Complexity In Bioprocess Development 6/18/2026

    Bioprocessing faces mounting pressure to compress timelines, especially for mAbs, while complex modalities like bispecifics and gene therapies introduce technical challenges. Process intensification, scale-up translation, and comparability risks remain critical hurdles.